Archive · 25 Jan 2026
Trump Pushes Global Drug Price Overhaul
President Trump wants other countries to pay more for medicines so that Americans can pay less.
He has a plan called 'Most Favored Nation' where drug companies promise to charge the U.S. the same or less than what other rich countries pay.
Some countries, like the U.K., have agreed to pay more.
Big Pharma companies are trying to make this happen, but it's not easy.
Some experts think it might not work well, and the U.S. might not save as much money as hoped.
For now, drug companies are not seeing big losses, but the future is uncertain.
Americans pay about three times more for branded prescription drugs than other wealthy nations.
Trump's 'Most Favored Nation' policy aims to tie U.S. drug prices to those in other wealthy countries.
Drugmakers have agreed to charge the U.S. no more than what other wealthy countries pay for newly launched medicines.
The U.K. has agreed to increase drug prices as part of a trade deal with the Trump administration.
Pfizer's CEO stated that the company would stop supplying France if forced to reduce U.S. prices to France's level.
- Who
- President Trump, Big Pharma, U.S. and foreign governments, pharmaceutical companies like Pfizer and AstraZeneca
- What
- Efforts to make foreign countries pay more for drugs to lower U.S. drug prices
- When
- Ongoing, with recent developments under the Trump administration
- Where
- United States and other wealthy nations, including the U.K., Germany, and France
- Why
- To reduce the high cost of drugs in the U.S. by leveraging international pricing
- U.S. Drug Prices
- About three times higher than other wealthy nations
- Trump's Policy
- Most Favored Nation (MFN) policy to tie U.S. prices to foreign prices
- Key Commitments
- Drugmakers agreed to charge the U.S. no more than other wealthy countries for new medicines
- U.K. Agreement
- Increased drug prices as part of a trade deal with the Trump administration
- Pfizer's Stance
- Would stop supplying France if forced to reduce U.S. prices to France's level
- Madrigal's Drug
- Seeking to sell Rezdiffra in Germany at a similar price to the U.S.
- J&J's Impact
- Several hundred million dollars in annual sales reduction due to MFN policy